Improving blood pressure control: Increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial

Journal of Clinical Hypertension

Volumn 10, Issue 6, 2008, Pages 450-458

  White, William B ^a   Calhoun, David A ^b   Samuel, Rita ^c   Taylor, Addison A ^d   Zappe, Dion H ^c   Purkayastha, Das ^c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ABDOMINAL PAIN; ADULT; AGE; AGED; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; TENDON RUPTURE; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 55249099160     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08259.x     Document Type: Article

References (23)

1. Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 60 prospective studies. Lancet. 2002;14:1903-1913.
2. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
3. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high BP. JAMA. 2003;289:2560-2572.
4. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1054.
5. Ruddy MC, Kostis JB. Angiotensin receptor antagonists. In Oparil S, Weber MA, eds. Hypertension. Philadelphia, PA: WB Saunders Co; 2000:621-637.
6. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled parallel-group trial. Clin Ther. 2001;23:833-850.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenelol. Lancet. 2002;359:995-1003.
8. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363(9426):2049-2051.
9. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
10. Brenner BM, Cooper ME, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:857-860.
12. Moser M. Update on the management of hypertension: Recent clinical trials and the JNC 7. J Clin Hypertens (Greenwich). 2004;6(10 suppl 2):4-13.
13. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood prBssure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716.
14. Medical Dictionary for Regulatory Activities Terminology (MedDRA). Version 3.3. Reston, VA: MedDRA MSSO, December 2000.
15. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861-866.
16. Kjeldsen SE, Os I, Hoieggen A, et al. Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005;5:17-22.
17. Wagstaff AJ. Valsartan/hydrochlorothiazide: A review of its use in the management of hypertension. Drugs. 2006;66:1881-1901.
18. Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press. 2001;10:230-237.
19. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl. 2003;1:36-43.
20. Rosenstock J, Rossi L, Lin CS, et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998;23:433-440.
21. Lacourciere Y, Poirer L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens. 2003;16:1036-1042.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
23. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.